Sysmex Journal International
2014Vol.24 No.1
RepublishedMasatoshi YAMASAKI, Akane SEKI, Michiko YOSHIMOTO, and Toru SUGIYAMA
Scientific Research Division, Scientific Affairs, Sysmex Corporation
In 2008, OSNA ( One Step Nucleic acid Amplification ) was approved by the Ministry of Health in Japan. Following the approval, OSNA has been applied as a routine diagnostic tool for rapid detection of metastases in sentinel lymph node samples from breast cancer patients.
We performed the basic evaluation of Lynoamp BC on the basis of the following criteria :
1) Reproducibility, 2) Linearity, 3) Inter-vial variability test, 4) Positive and negative accuracy, 5) Long-term stability, and 6) Interference materials.
As a result, it turned out that the result of the basic evaluation of Lynoamp BC was excellent. We expect that OSNA can contribute to standardizing breast cancer treatment by minimizing the known variability in the methodology and accuracy of conventional SLN diagnosis.
OSNA, RD-100i , Lynoamp BC, Cytokeratin 19 (CK19)
This article is translated and republished from the Sysmex Journal Web Vol. 12 No. 1, 2011. (Japanese)